The latest news:

• FDA Grants Fast Track Designation to Tocagen’s Toca 511 & Toca FC for Treatment of Recurrent High Grade Glioma         Exciting news.  This will hopefully speed up the approval of this immunotherapy for brain tumors!  Notice that they mention the Musella Foundation!  
  



• Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.         This study says that adding carboplatin to Avastin actually is worse than using Avastin alone for recurrent gbm.
  



• Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy.         Although it is a small study, impressive results. Sounds similar  to a treatment that was done at Duke years ago which also showed good results but for unknown reasons development was stopped.
  



• Epigenetic Driver of Glioblastoma Provides New Therapeutic Target         Brilliant research. This type of thinking may lead to a major advance quickly. There is research on using this approach for ovarian cancer (in the test tube) that showed good results.
  



• An Evidence-Based Review of Alternating Electric Fields Therapy for Malignant Gliomas.        This should be included in the standard of care for newly diagnosed glioblastomas. (Disclaimer: Novocure, the company that makes Optune, is a sponsor of our organization).    
  



• Ottawa Hospital launches world's first clinical trial of double-virus cancer treatment         Interesting.  Makes a lot of sense.
  

BrainTumor Co-Payment Assistance Program Status:

• OPEN to new applicants